Creo Medical Group (LON:CREO) Issues Quarterly Earnings Results

Creo Medical Group (LON:CREO) posted its quarterly earnings data on Wednesday. The company reported GBX (2) earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative net margin of 268.57% and a negative return on equity of 38.29%.

Creo Medical Group Stock Down 1.9%

LON CREO traded down GBX 0.18 on Friday, reaching GBX 9.62. 1,313,757 shares of the stock traded hands, compared to its average volume of 789,479. Creo Medical Group has a 12 month low of GBX 9.50 and a 12 month high of GBX 18.50. The company has a market cap of £46.72 million, a price-to-earnings ratio of 9.62 and a beta of 1.56. The company has a fifty day moving average price of GBX 12.62 and a 200-day moving average price of GBX 12.82. The company has a debt-to-equity ratio of 8.09, a quick ratio of 2.19 and a current ratio of 2.79.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating and issued a GBX 40 target price on shares of Creo Medical Group in a research report on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.